Cureus · 2024 · 17 citations · 6 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyGastroenterologyGastrointestinal PharmacotherapyDiabetes MellitusFunctional Gastrointestinal DisordersGastrointestinal DiseaseGastrointestinal PharmacologyGlucagon TherapyGlucagon-like Peptide-1 Receptor AgonistsDiabetic Gastroparesis TreatmentGastroparesis PharmacotherapyGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingGlucagon-like PeptidesWeight Loss Drug
Semaglutide, an agonist of the glucagon-like peptide-1 receptor, is frequently used in the treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a reason for its use. However, if a patient is already experiencing bloating, nausea, abdominal pain, and discomfort in the abdomen, it is not recommended to use it due to concern about aggravating these symptoms. Although it is often well tolerated, there are occasions when it can have several gastrointestinal side effects. Therefore, we report a case of a patient who started taking semaglutide and later developed gastroparoresis.
6